Thursday, November 14, 2024

Regeneron accused of ‘fraudulent’ drug-pricing reporting for eye drug Eylea

Must read




The Department of Justice on Wednesday accused drug maker Regeneron Pharmaceuticals Inc. of fraudulent practices related the pricing of its blockbuster vision-impairment drug Eylea, boosting its sales in the process.



Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article